New drug aims to tame overactive immune response in sepsis
NCT ID NCT06694701
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests emapalumab, a drug that blocks a protein called interferon-gamma, in 75 adults with sepsis caused by a specific immune overreaction. The goal is to see if the drug can reduce organ failure, measured by a drop in the SOFA score. Participants are in ICUs across Greece and receive either emapalumab or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Emapalumab (a drug that blocks interferon-gamma, a protein involved in inflammation)
What this could lead to
If it works, this could point toward a targeted treatment for a specific type of sepsis, potentially reducing organ failure and improving survival in ICU patients.
What could go wrong
This is an early phase 2 trial with only 75 participants, so results may not apply to all sepsis patients. The drug may not improve outcomes or could cause side effects like increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1st Department of Internal Medicine, Thriasio Elefsis General Hospital
Elefsina, Attica, Greece
-
1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
Thessaloniki, Greece
-
3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
-
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
-
Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
Kifissia, Attica, Greece
-
Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
Thessaloniki, Greece
-
Intensive Care Unit I, KAT Attica General Hospital
Athens, Greece
-
Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
-
Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
-
Intensive Care Unit, 424 General Military Training Hospital
Thessaloniki, Greece
-
Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
Thessaloniki, Greece
-
Intensive Care Unit, Alexandroupolis University General Hospital
Alexandroupoli, Greece
-
Intensive Care Unit, Asklipieio Voulas General Hospital
Athens, Greece
-
Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
Thessaloniki, Greece
-
Intensive Care Unit, Ippokrateio Athens General Hospital
Athens, Greece
-
Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
Thessaloniki, Greece
-
Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
Athens, Greece
-
Intensive Care Unit, Laiko Athens General Hospital
Athens, Greece
-
Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
Thessaloniki, Greece
-
Intensive Care Unit, Patras University General Hospital
Pátrai, Greece
-
Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
Thessaloniki, Greece
-
Intensive Care Unit, University General Hospital of Heraklion
Heraklion, Crete, Greece
-
New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
-
Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
Athens, Greece